Posttransplantation lymphoproliferative disorder (PTLD) is a serious complication of organ transplantation, with an incidence of 0.8% to 20% in heart transplant (HTx) recipients, and standard treatment may be too toxic in some cases. Rituximab is an anti-CD20 monoclonal antibody that has demonstrated efficacy in patients with various lymphoid malignancies and has been demonstrated effective in ...

Immunosuppressive therapy for transplanted patients exposes them to a high risk of developing posttransplantation lymphoproliferative disorders (PTLD). We report the case of a child undergoing heart transplantation at seven months of age who developed PTLD at nine years of age, diagnosed by resection of a pulmonary nodule.

Chronic myeloid leukemia (CML) rarely develops following organ transplantation. Chronic immunosuppressive therapy is believed to be responsible for secondary malignancies, mainly the tumors of the lymphoid tissue and skin neoplasms.1-3 The known mechanisms involved in the development of secondary malignancies include decreased immunosurveillance due to chronic immunosuppression and direct tumor...

BACKGROUND Cancer is a well-recognized complication of organ transplantation. The pattern of malignancies that occur in the paediatric graft population is different from that in the general paediatric population and in the population of adult organ transplant recipients. METHODS We reviewed medical records from 240 consecutive paediatric renal transplantations performed in 219 children, aged ...

Abstract Background Pneumocystis jirovecii pneumonia (PCP) is a potentially deadly infection afflicting the immunocompromised population, including solid organ transplant recipients. Several risk factors have been described, acute rejection, lymphopenia, and cytomegalovirus (CMV) infection. However, little known regarding imparted by posttransplant lymphoproliferative disorder (PTLD). Methods W...

Posttransplant lymphoproliferative disorder (PTLD) is a spectrum of diseases that involves abnormal lymphoid and/or plasmacytic proliferation in patients with solid organ or hematopoietic cell transplantation. It is a condition with a low incidence of 3.5-4.3% in liver transplant (LT) recipients. This case involves a 63-year-old male with history of LT for chronic HCV induced cirrhosis who pres...

Although several risk factors for posttransplant lymphoproliferative disease (PTLD) after solid organ transplantation have been identified, the immunosuppressive regimen probably as most important one, their exact pathogenic role and relevance is still unclear. In hematopoietic stem cell transplantation, HLA mismatching also is a risk factor. We analyzed factors possibly associated with develop...

Posttransplantation lymphoproliferative disorder (PTLD) represents a spectrum of Epstein-Barr virus (EBV)-driven lymphoid proliferation related to immunosuppressive therapy. We here report a case of a 21-year-old male with PTLD of liver and renal allograft simultaneously after renal transplantation. MRI depicted solid mass lesions, which were hypointense on T1-weighted images and heterogeneousl...

Between March 27, 1989 and December 31, 1997, 1316 kidney transplantations alone were performed under tacrolimus-based immunosuppression at our center. Posttransplant lymphoproliferative disorders (PTLD) developed in 25 (1.9%) cases; the incidence in adults was 1.20/c (1511217). whereas in pediatric patients it was 10.IO/c (10/99; P<.OOOl). PTLD was diagnosed 21.0±22.5 months after transplantat...